EGF的细胞膜表面受体:表皮生长因子的受体(EGFR),属于酪氨酸激酶受体家族,除了能调节正常细胞的生理功能,也能够调节肿瘤细胞增殖、存活和分化。 所以将EGF药物制剂、EGFR以及癌症关联起来似乎顺理成章? 我们还是先简单回顾一下癌症(cancer)或者肿瘤(tum...
Cimavax EGF(registered trademark) cancer vaccine for non small cell lung cancer (NSCLC) therapy: Partial report of a phase III clinical trialE., NeningerP.C., RodriguezX., PopaB., GarciaC., ViadaG., GonzalezS., AscarateilT., Crombet...
Endometrial cancer (EC) is the most common uterine malignancy in industrialized countries and is the most frequent gynecologic cancer in the United States with an estimated 60,050 new cases in 2016. Traditionally observed in peri-, postm... S Taurin,CH Yang,M Reyes,... - 《Cancer Research...
the results allowing the cuban regulatory agency (cecmed) to grant the sanitary registration to the cimavax-egf cancer vaccine for advanced non-small cell lung cancer (nsclc) are shown. this was the first registration of a therapeutic vaccine in cuba and also the first registration of a lung ...
The molecular mechanisms driving metastatic progression in triple-negative breast cancer (TNBC) patients are poorly understood. In this study, we demonstrate that epidermal growth factor-like 9 (EGFL9) is significantly upregulated in basal-like breast ca
《Journal of Cancer》发表了一项“Cimavax-EGF治疗晚期非小细胞肺癌(NSCLC)”的令人惊艳的临床研究结果。入组的106例晚期非小细胞肺癌患者(脑转移除外),在接受一线治疗(如放化疗、铂类双药或单药化疗)待病情稳定后,入组接受CIMAvax-EGF治疗,经过14.2个月的中位随访,结果显示如下: ...
the results allowing the cuban regulatory agency (cecmed) to grant the sanitary registration to the cimavax-egf cancer vaccine for advanced non-small cell lung cancer (nsclc) are shown. this was the first registration of a therapeutic vaccine in cuba and also the first registration of a lung ...
Crosstalk between cancer cells and macrophages promotes OSCC cell migration and invasion through a CXCL1/EGF positive feedback loop C-X-C motif chemokine ligand 1 (CXCL1) and epithelial growth factor (EGF) are highly secreted by oral squamous cell carcinoma (OSCC) cells and tumor-associ... ...
This application describes a prolongation of survival in cancer patients, by treating the patient with a HER dimerization inhibitor, such as pertuzumab, the patient, the level of TGF-α or EGF here rise in has occurred. The present invention relates to a method for prolonging the survival of ...
[2]Flores Vega YI,et al.Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. J Cancer. 2023 Apr 1;14(5):874-879. doi:10.7150/jca.67189. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088885/ ...